CPT code 64605 denotes a neurodestructive injection performed at or near the trigeminal nerve to ablate nerve tissue and disrupt sensory or motor function in the face or scalp. This procedure is clinically significant as a treatment option for severe facial pain syndromes such as trigeminal neuralgia and may be used to manage refractory neuropathic pain or to intentionally impair facial motor function for therapeutic reasons. Nationally, the code is relevant to payers and providers involved in pain management, neurosurgery, and outpatient procedural care.

Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical indications and typical sites of service, how the code maps to procedural workflows, and what to expect in payer coverage considerations. The publication also summarizes benchmarks and common billing practices where available, highlights relevant policy updates affecting utilization and prior authorization, and situates CPT code 64605 within the broader clinical context of trigeminal nerve interventions.

This briefing is intended for national audiences of clinicians, coding professionals, and policy analysts seeking a practical summary of procedural intent, payer relevance, and topics to explore further when preparing claims or reviewing coverage policies.